

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



July 3, 2026

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takayuki Komamura, Director, Department Manager of Corporate Finance and Management Department (Telephone +81-263-25-9081)

Notice Concerning Status of Acquisition of Treasury Shares
(Acquisition of Treasury shares based on provisions of the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)

KISSEI PHARMACEUTICAL CO., LTD. (the "Company") announces status of acquisition of treasury shares pursuant to Article 156 of the Companies Act as applied pursuant to Article 165, Paragraph 3 of the Companies Act, which was announced on May 11, 2026, as follows.

1. Type of shares acquired: Common shares of the Company
2. Total number of shares acquired: 0 share
3. Total amount of shares acquired: 0 yen
4. Period of acquisition: Started on June 1, 2026 and ended on June 30, 2026 (based on contract date)
5. Acquisition method: Market purchases on the Tokyo Stock Exchange based on a discretionary trading contract regarding acquisition of own shares

(Reference)

1. Details of the resolution at the meeting of Board of Directors held on May 11, 2026
 - 1) Type of shares to be acquired: Common shares of the Company
 - 2) Total number of shares to be acquired: Up to 1,300,000 shares
(Percentage of total number of issued shares (excluding treasury shares) : 3.14%)
 - 3) Total acquisition cost: 6 billion yen (maximum)
 - 4) Acquisition period: From May 12, 2026 to December 31, 2026
 - 5) Acquisition method: Market purchases on the Tokyo Stock Exchange
 1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
 2. Market purchases based on a discretionary trading contract regarding acquisition of own shares
2. Cumulative number and value of own shares acquired so far based on the above resolution at the Board of Directors meeting (As of June 30, 2026)
 - 1) Total number of shares acquired: 0 share
 - 2) Total amount of shares acquired: 0 yen

-End-